Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Prehabilitation for radical prostatectomy: A multicentre randomized controlled trial.

Santa Mina D, Hilton WJ, Matthew AG, Awasthi R, Bousquet-Dion G, Alibhai SMH, Au D, Fleshner NE, Finelli A, Clarke H, Aprikian A, Tanguay S, Carli F.

Surg Oncol. 2018 Jun;27(2):289-298. doi: 10.1016/j.suronc.2018.05.010. Epub 2018 May 7.

PMID:
29937184
2.

A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores.

Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, Aprikian AG, Lacombe L, Fleshner NE, Gleave ME, Mes-Masson AM, Saad F, Karakiewicz PI.

Pathol Oncol Res. 2018 Apr 6. doi: 10.1007/s12253-018-0408-6. [Epub ahead of print]

PMID:
29623528
3.

Improving patient journey and quality of care: Summary from the 2nd Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Kassouf W, Aprikian A, Saad F, Breau RH, Kulkarni G, Guttman DM, Bagshaw K, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Brimo F, Chung P, Drachenberg D, Fradet Y, Jacobsen N, Morash C, Shayegan B, Gotto G, Zlotta A, Fleshner N, Siemens DR, Black PC.

Can Urol Assoc J. 2018 Mar 19. doi: 10.5489/cuaj.5246. [Epub ahead of print] No abstract available.

PMID:
29603921
4.

Changes in the levels of testosterone profile over time in relation to clinical parameters in a cohort of patients with prostate cancer managed by active surveillance.

Zakaria AS, Dragomir A, Kassouf W, Tanguay S, Aprikian A.

World J Urol. 2018 Mar 20. doi: 10.1007/s00345-018-2270-2. [Epub ahead of print]

PMID:
29560520
5.

The effect of statin use on the incidence of prostate cancer: A population-based nested case-control study.

Dawe DE, Ye X, Czaykowski P, Jassal D, Singh H, Skarsgard D, Aprikian A, Mahmud SM.

Int J Cancer. 2018 Jul 1;143(1):190-198. doi: 10.1002/ijc.31295. Epub 2018 Feb 16.

PMID:
29405283
6.

Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study.

Dragomir A, Aprikian A, Kapoor A, Finelli A, Pouliot F, Rendon R, Black PC, Moore R, Breau RH, Kawakami J, Drachenberg D, Lattouf JB, Tanguay S.

CMAJ Open. 2017 Dec 11;5(4):E834-E841. doi: 10.9778/cmajo.20170005.

7.

Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention.

Bramhecha YM, Guérard KP, Rouzbeh S, Scarlata E, Brimo F, Chevalier S, Hamel L, Dragomir A, Aprikian AG, Lapointe J.

Mol Cancer Res. 2018 Jan;16(1):115-123. doi: 10.1158/1541-7786.MCR-17-0270. Epub 2017 Oct 9.

PMID:
28993510
8.

Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer.

Hu J, Aprikian AG, Cury FL, Vanhuyse M, Zakaria AS, Richard PO, Perreault S, Dragomir A.

Clin Genitourin Cancer. 2017 Sep 5. pii: S1558-7673(17)30266-5. doi: 10.1016/j.clgc.2017.08.011. [Epub ahead of print]

PMID:
28943330
9.

Treatment patterns and trends in patients dying of prostate cancer in Quebec: a population-based study.

Dragomir A, Rocha J, Vanhuyse M, Cury FL, Kassouf W, Hu J, Aprikian AG.

Curr Oncol. 2017 Aug;24(4):240-248. doi: 10.3747/co.24.3598. Epub 2017 Aug 31.

10.

Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.

Audet-Walsh É, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, Vernier M, Caron M, Bourque G, Scarlata E, Hamel L, Brimo F, Aprikian AG, Lapointe J, Chevalier S, Giguère V.

Genes Dev. 2017 Jun 15;31(12):1228-1242. doi: 10.1101/gad.299958.117. Epub 2017 Jul 19.

11.

Pathology review impacts clinical management of patients with T1-T2 bladder cancer.

Traboulsi SL, Brimo F, Yang Y, Maedler C, Prévost N, Tanguay S, Aprikian AG, Kassouf W.

Can Urol Assoc J. 2017 Jun;11(6):188-193. doi: 10.5489/cuaj.4126.

12.

Phase I Clinical Trial of Everolimus Combined with Trimodality Therapy in Patients with Muscle-Invasive Bladder Cancer.

Bachir BG, Souhami L, Mansure JJ, Cury F, Vanhuyse M, Brimo F, Aprikian AG, Tanguay S, Sturgeon J, Kassouf W.

Bladder Cancer. 2017 Apr 27;3(2):105-112. doi: 10.3233/BLC-160090.

13.

Health care services utilization during the last 6 months of life among patients with bladder cancer who underwent radical cystectomy in Quebec, Canada.

Zakaria AS, Santos F, Dragomir A, Kassouf W, Tanguay S, Aprikian A.

Urol Oncol. 2017 Sep;35(9):539.e1-539.e7. doi: 10.1016/j.urolonc.2017.04.005. Epub 2017 May 4.

PMID:
28479117
14.

Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study.

Rocha J, Aprikian AG, Vanhuyse M, Cury FL, Hu J, Prévost N, Dragomir A.

CMAJ Open. 2017 Mar 28;5(1):E265-E272. doi: 10.9778/cmajo.20160082. eCollection 2017 Jan-Mar.

15.

Asporin is a stromally expressed marker associated with prostate cancer progression.

Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, Aprikian A, Chevalier S, Thomson AA.

Br J Cancer. 2017 Mar 14;116(6):775-784. doi: 10.1038/bjc.2017.15. Epub 2017 Feb 2.

16.

Sclerosing epithelioid fibrosarcoma metastasizing to the penile shaft.

Bell MD, Brimo F, Jung S, Aprikian AG.

Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E398-E400. doi: 10.5489/cuaj.3528. Epub 2016 Nov 10.

17.

Quality indicators in the management of bladder cancer: A modified Delphi study.

Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Jewett M, Kulkarni G, Lacombe L, Moore R, Morash C, North S, Rendon R, Saad F, Shayegan B, Siemens R, So A, Sridhar SS, Traboulsi SL, Kassouf W.

Urol Oncol. 2017 Jun;35(6):328-334. doi: 10.1016/j.urolonc.2016.12.003. Epub 2017 Jan 3.

PMID:
28065393
18.

Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer.

Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L.

J Clin Oncol. 2017 Jan 10;35(2):201-207. Epub 2016 Nov 21.

PMID:
27870566
19.

A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks.

Pellerin C, McKercher G, Aprikian AG, Saad F, Lacombe L, Carmel M, Chevalier S.

Biopreserv Biobank. 2016 Oct;14(5):383-389. Epub 2016 Jun 21.

PMID:
27327090
20.

Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate Cancer.

Klil-Drori AJ, Tascilar K, Yin H, Aprikian A, Bitton A, Azoulay L.

Am J Epidemiol. 2016 Jul 1;184(1):15-22. doi: 10.1093/aje/kwv307. Epub 2016 Jun 6.

21.

Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Kassouf W, Aprikian A, Black P, Kulkarni G, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Alam T, Brimo F, Blais N, Booth C, Chin J, Chung P, Drachenberg D, Fradet Y, Jewett M, Moore R, Morash C, Shayegan B, Gotto G, Fleshner N, Saad F, Siemens DR.

Can Urol Assoc J. 2016 Jan-Feb;10(1-2):E46-80. doi: 10.5489/cuaj.3583. Epub 2016 Feb 8. No abstract available.

22.

Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.

Bell MD, Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W.

World J Urol. 2016 Oct;34(10):1405-9. doi: 10.1007/s00345-016-1795-5. Epub 2016 Feb 23.

PMID:
26906030
23.

Survival after Radical Cystectomy for Bladder Cancer in Relation to Prior Non-Muscle Invasive Disease in Quebec.

Zakaria AS, Santos F, Kassouf W, Tanguay S, Aprikian A.

Urol Int. 2016;97(1):49-53. doi: 10.1159/000444093. Epub 2016 Feb 11.

PMID:
26863611
24.

De novo steroid biosynthesis in human prostate cell lines and biopsies.

Sakai M, Martinez-Arguelles DB, Aprikian AG, Magliocco AM, Papadopoulos V.

Prostate. 2016 May;76(6):575-87. doi: 10.1002/pros.23146. Epub 2016 Feb 4.

PMID:
26841972
25.

Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.

Sanyal C, Aprikian AG, Cury FL, Chevalier S, Dragomir A.

Cancer. 2016 Apr 1;122(7):1085-96. doi: 10.1002/cncr.29892. Epub 2016 Feb 1.

26.

The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases.

Chevalier S, Moffett S, Turcotte E, Luz M, Chauvette L, Derbekyan V, Scarlata E, Zouanat F, Aprikian AG, Anidjar M.

EJNMMI Res. 2015 Dec;5(1):77. doi: 10.1186/s13550-015-0155-6. Epub 2015 Dec 30.

27.

Predictors of costs associated with radical cystectomy for bladder cancer: A population-based retrospective cohort study in the province of Quebec, Canada.

Santos F, Dragomir A, Zakaria AS, Kassouf W, Aprikian A.

J Surg Oncol. 2016 Feb;113(2):223-8. doi: 10.1002/jso.24132. Epub 2015 Dec 22.

PMID:
26696270
28.

CUA guidelines on the management of non-muscle invasive bladder cancer.

Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zlotta A, Fairey A, So A, Lacombe L, Rendon R, Aprikian AG, Siemens DR, Izawa JI, Black P.

Can Urol Assoc J. 2015 Sep-Oct;9(9-10):E690-704. doi: 10.5489/cuaj.3320. Epub 2015 Oct 13. No abstract available.

29.

Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer.

Cerantola Y, Dragomir A, Tanguay S, Bladou F, Aprikian A, Kassouf W.

Urol Oncol. 2016 Mar;34(3):119.e1-9. doi: 10.1016/j.urolonc.2015.09.010. Epub 2015 Oct 24.

PMID:
26602178
30.

Evaluation of RNA-binding motif protein 3 expression in urothelial carcinoma of the bladder: an immunohistochemical study.

Florianova L, Xu B, Traboulsi S, Elmansi H, Tanguay S, Aprikian A, Kassouf W, Brimo F.

World J Surg Oncol. 2015 Nov 14;13:317. doi: 10.1186/s12957-015-0730-3.

31.

Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada.

Blanc-Lapierre A, Spence A, Karakiewicz PI, Aprikian A, Saad F, Parent MÉ.

BMC Public Health. 2015 Sep 18;15:913. doi: 10.1186/s12889-015-2260-x.

32.

Inverted urothelial carcinoma: a series of 12 cases with a wide morphologic spectrum overlapping with the large nested variant.

Brimo F, Dauphin-Pierre S, Aprikian A, Kassouf W, Tanguay S, Ajise O, Dongo C, Bégin LR.

Hum Pathol. 2015 Oct;46(10):1506-13. doi: 10.1016/j.humpath.2015.06.010. Epub 2015 Jun 26.

PMID:
26255235
33.

Health-care services utilization and costs associated with radical cystectomy for bladder cancer: a descriptive population-based study in the province of Quebec, Canada.

Santos F, Dragomir A, Zakaria AS, Kassouf W, Aprikian A.

BMC Health Serv Res. 2015 Aug 5;15:308. doi: 10.1186/s12913-015-0972-3.

34.

Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.

Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L.

Eur Urol. 2016 Jul;70(1):56-61. doi: 10.1016/j.eururo.2015.06.022. Epub 2015 Jun 29.

PMID:
26138040
35.

BCG-related renal granulomas managed conservatively: A case series.

Al-Qaoud T, Brimo F, Aprikian AG, Andonian S.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E200-3. doi: 10.5489/cuaj.2664.

36.

Urologist referral delay and its impact on survival after radical cystectomy for bladder cancer.

Santos F, Dragomir A, Kassouf W, Franco E, Aprikian A.

Curr Oncol. 2015 Feb;22(1):e20-6. doi: 10.3747/co.22.2052.

37.

Radical cystectomy in patients over 80 years old in Quebec: A population-based study of outcomes.

Zakaria AS, Santos F, Tanguay S, Kassouf W, Aprikian AG.

J Surg Oncol. 2015 Jun;111(7):917-22. doi: 10.1002/jso.23887. Epub 2015 Feb 8.

PMID:
25663440
38.

Enhanced recovery pathway for radical prostatectomy: Implementation and evaluation in a universal healthcare system.

Abou-Haidar H, Abourbih S, Braganza D, Qaoud TA, Lee L, Carli F, Watson D, Aprikian AG, Tanguay S, Feldman LS, Kassouf W.

Can Urol Assoc J. 2014 Nov;8(11-12):418-23. doi: 10.5489/cuaj.2114.

39.

Clinical management and burden of prostate cancer: a Markov Monte Carlo model.

Sanyal C, Aprikian A, Cury F, Chevalier S, Dragomir A.

PLoS One. 2014 Dec 4;9(12):e113432. doi: 10.1371/journal.pone.0113432. eCollection 2014.

40.

High hospital and surgeon volume and its impact on overall survival after radical cystectomy among patients with bladder cancer in Quebec.

Santos F, Zakaria AS, Kassouf W, Tanguay S, Aprikian A.

World J Urol. 2015 Sep;33(9):1323-30. doi: 10.1007/s00345-014-1457-4. Epub 2014 Dec 4.

PMID:
25471670
41.

Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial.

Santa Mina D, Matthew AG, Hilton WJ, Au D, Awasthi R, Alibhai SM, Clarke H, Ritvo P, Trachtenberg J, Fleshner NE, Finelli A, Wijeysundera D, Aprikian A, Tanguay S, Carli F.

BMC Surg. 2014 Nov 13;14:89. doi: 10.1186/1471-2482-14-89.

42.

Outcome of repeated prostatic biopsy during active surveillance: implications for focal therapy.

Barayan GA, Aprikian AG, Hanley J, Kassouf W, Brimo F, Bégin LR, Tanguay S.

World J Urol. 2015 Sep;33(9):1275-80. doi: 10.1007/s00345-014-1433-z. Epub 2014 Nov 12.

PMID:
25387875
43.

Postoperative mortality and complications after radical cystectomy for bladder cancer in Quebec: A population-based analysis during the years 2000-2009.

Zakaria AS, Santos F, Dragomir A, Tanguay S, Kassouf W, Aprikian AG.

Can Urol Assoc J. 2014 Jul;8(7-8):259-67. doi: 10.5489/cuaj.1997.

44.

An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.

Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M, Zarenda M, Chin J.

Prostate Cancer Prostatic Dis. 2014 Dec;17(4):320-4. doi: 10.1038/pcan.2014.24. Epub 2014 Sep 2.

PMID:
25179591
45.

Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy.

Brimo F, Xu B, Scarlata E, Bégin LR, Spatz A, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A.

Hum Pathol. 2014 Oct;45(10):2006-13. doi: 10.1016/j.humpath.2014.06.014. Epub 2014 Jul 2.

PMID:
25152453
46.

Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison.

Dragomir A, Cury FL, Aprikian AG.

CMAJ Open. 2014 Apr 24;2(2):E60-8. doi: 10.9778/cmajo.20130037. eCollection 2014 Apr.

47.

Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer.

Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W.

Urol Oncol. 2015 Feb;33(2):66.e25-31. doi: 10.1016/j.urolonc.2014.06.008. Epub 2014 Jul 15.

PMID:
25037483
48.

Royal College surgical objectives of urologic training: A survey of faculty members from Canadian training programs.

Zakaria AS, Haddad R, Dragomir A, Kassouf W, Andonian S, Aprikian AG.

Can Urol Assoc J. 2014 May;8(5-6):167-72. doi: 10.5489/cuaj.1720.

49.

Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy.

Patel N, Souhami L, Mansure JJ, Duclos M, Aprikian A, Faria S, David M, Cury FL.

Brachytherapy. 2014 Sep-Oct;13(5):450-5. doi: 10.1016/j.brachy.2014.05.005. Epub 2014 Jul 10.

PMID:
25023396
50.

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.

Dragomir A, Dinea D, Vanhuyse M, Cury FL, Aprikian AG.

BMC Health Serv Res. 2014 Jun 13;14:252. doi: 10.1186/1472-6963-14-252.

Supplemental Content

Loading ...
Support Center